Thieler Law Corp advises investors with losses exceeding $100,000 of the August 3, 2018 lead plaintiff deadline in a class action lawsuit filed against MabVax Therapeutics Holdings Inc (NASDAQ: MBVX) (“MabVax” or “the Company”). The suit is pending in the U.S. District Court for the Southern District of California and investors, who purchased MabVax Therapeutics Holdings Inc securities between March 14, 2016 and May 18, 2018, have until August 3, 2018 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class.

If you purchased MabVax Therapeutics Holdings Inc securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class.

The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that MabVax’s internal controls over financial reporting were materially weak and deficient; MabVax had incorrectly calculated and reported beneficial ownership of MabVax shares, and permitted improper influence or control over MabVax, and/or MabVax’s officers and directors by certain shareholders; and as a result, MabVax’s financial statements and defendants’ statements about MabVax’s business, operations, and prospects were materially false and misleading at all relevant times.

On May 24, 2018, the Company got notice from the Listing Qualifications Department of The Nasdaq Stock Market indicating that the Company is not in compliance with Nasdaq Listing Rule, which requires the timely filing of periodic reports with the U.S. Securities and Exchange Commission. The notice was sent as a result of the delay in the filing of the Company's Quarterly Report on Form 10-Q for the period ending March 31, 2018.

Following this news, NASDAQ: MBVX dropped significantly, thereby injuring investors.

If you were negatively impacted by your investment in MabVax Therapeutics Holdings Inc securities between March 14, 2016 and May 18, 2018 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation.

Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/

or

Facsimile: +1 (619) 785 – 3185